I'm not a scientist by training but the MoA and rationale for $ABOS targeting Amyloid β Oligomer makes sense. See helpful article here: https://t.co/lKIz5piFA7
278 followers
75,082 followers
New Research: ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease: Alzheimer’s disease (AD) is an age-related neurodegenerative disease that affects 50 million people worldwide, with 10… https://t.co/lW5nvMY
48 followers
RT @AcumenPharm: .@FrontNeurosci, a peer-reviewed journal, published a summary of preclinical evidence supporting ACU193, Acumen's monoclon…
6,870 followers
"More than 25 negative randomized clinical trials (RCTs) have evaluated Aβ-targeting therapeutics, yet none has directly evaluated whether selective blockage of disease-relevant AβOs can stop or reverse AD-associated cognitive decline." New $ABOS paper. ht